183 related articles for article (PubMed ID: 36177815)
1. Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis.
Behrangi E; Barough MS; Khoramdad M; Hejazi P; Koltapeh MP; Goodarzi A
J Cosmet Dermatol; 2022 Dec; 21(12):6644-6652. PubMed ID: 36177815
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
3. Systematic review - alopecia areata and tofacitinib in paediatric patients.
Bandeira A; Albino-Teixeira A; Magina S
Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
[TBL] [Abstract][Full Text] [Related]
5. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
Asilian A; Mohammadian P; Shahmoradi Z
J Cosmet Dermatol; 2024 Mar; 23(3):886-890. PubMed ID: 37933534
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
8. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Kibbie J; Kines K; Norris D; Dunnick CA
Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
[TBL] [Abstract][Full Text] [Related]
9. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
Huang J; Deng S; Li J; Tang Y; Liu F; Liu Y; Rao S; Shi W
Acta Derm Venereol; 2023 Nov; 103():adv13475. PubMed ID: 37955531
[TBL] [Abstract][Full Text] [Related]
10. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
Guo L; Feng S; Sun B; Jiang X; Liu Y
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
[TBL] [Abstract][Full Text] [Related]
11. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
16. [Alopecia areata with good response to tofacitinib].
Maksimow A; Stintzing D; Wohlrab J
Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Cheng MW; Kehl A; Worswick S; Goh C
J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
[TBL] [Abstract][Full Text] [Related]
18. Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
Perche P; Purvis C; Pichardo R
J Drugs Dermatol; 2022 Dec; 21(12):1366-1368. PubMed ID: 36468955
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
Youssef S; Lavian J; Lee EY; Fan W; Bordone LA
J Am Acad Dermatol; 2023 May; 88(5):1125-1127. PubMed ID: 35551958
[No Abstract] [Full Text] [Related]
20. Experience with oral tofacitinib in severe alopecia areata with different clinical responses.
Dincer Rota D; Emeksiz MAC; Erdogan FG; Yildirim D
J Cosmet Dermatol; 2021 Sep; 20(9):3026-3033. PubMed ID: 33533091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]